PARP inhibitor resistance: the underlying mechanisms and clinical implications
Central South University · Hunan Cancer Hospital · +1 more institution
Abstract
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) polymerase (PARP) have been approved for ovarian cancer and breast cancer indications. However, PARPi resistance is ubiquitous in clinic. More than 40% BRCA1/2-deficient patients fail to respond to PARPi. In addition, lots of patients acquire PARPi resistance with prolonged oral administration of PARPi. Homologous recombination repair deficient (HRD), as an essential prerequisite of synthetic lethality, plays a vital role in killing tumor cells. Therefore, Homologous recombination repair restoration (HRR)…
Citation impact
- FWCI
- 22.92
- Percentile
- 100%
- References
- 166
Authors
6- HLHe Li
Central South University, Hunan Cancer Hospital
- ZLZhaoyi Liu
Central South University, Hunan Cancer Hospital
- NWNayiyuan Wu
Central South University, Hunan Cancer Hospital
- YCYongchang Chen
Central South University, Hunan Cancer Hospital
- QCQuan Cheng
Central South University, Xiangya Hospital Central South University
Topics & keywords
- Synthetic lethality
- DNA repair
- PARP inhibitor
- Poly ADP ribose polymerase
- Biology
- Homologous recombination
- Cancer research
- DNA damage
- Good health and well-being